GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GenMont Biotech 3164.TW · TWD

Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

16.65

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 401.2m

FY2016FY2025

Net income

TWD 57.2m

FY2016FY2025

Free cash flow

TWD 69.9m

FY2016FY2025

Shareholders' equity

TWD 1.33bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 401.2mTWD 385.4mTWD 318.0mTWD 368.5mTWD 427.9mTWD 325.2mTWD 346.2mTWD 406.5mTWD 380.7mTWD 540.8m
Gross profitTWD 251.6mTWD 238.2mTWD 211.2mTWD 256.7mTWD 299.3mTWD 215.4mTWD 229.7mTWD 277.5mTWD 264.6mTWD 310.1m
Research and developmentTWD 45.3mTWD 45.3mTWD 46.9mTWD 59.4mTWD 25.5mTWD 26.3mTWD 27.1mTWD 27.7mTWD 29.2mTWD 28.9m
Operating incomeTWD 57.8mTWD 40.1mTWD 7.0mTWD 60.2mTWD 143.5mTWD 77.0mTWD 76.8mTWD 122.8mTWD 109.1m−TWD 18.1m
Net incomeTWD 57.2mTWD 57.3mTWD 33.0mTWD 57.0mTWD 113.1mTWD 60.9mTWD 57.5mTWD 158.0mTWD 45.6m−TWD 235.9m
Diluted earnings per share0.730.650.380.661.300.710.651.760.52-2.65

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 1.67bnTWD 1.71bnTWD 1.65bnTWD 1.70bnTWD 1.70bnTWD 1.61bnTWD 1.57bnTWD 1.66bnTWD 1.50bnTWD 1.40bn
Cash and short-term investmentsTWD 432.8mTWD 425.8mTWD 328.3mTWD 400.9mTWD 421.7mTWD 465.1mTWD 526.5mTWD 926.9mTWD 371.9mTWD 302.8m
Total liabilitiesTWD 215.4mTWD 229.1mTWD 204.1mTWD 198.6mTWD 173.6mTWD 131.0mTWD 123.0mTWD 95.6mTWD 129.4mTWD 124.1m
DebtTWD 110.3mTWD 118.6mTWD 58.3mTWD 34.5mTWD 32.7mTWD 34.3mTWD 32.7mTWD 187,000TWD 1.4mTWD 1.4m
Shareholders' equityTWD 1.33bnTWD 1.35bnTWD 1.32bnTWD 1.35bnTWD 1.38bnTWD 1.33bnTWD 1.38bnTWD 1.49bnTWD 1.34bnTWD 1.28bn
Shares outstanding78m87m87m87m87m86m89m90m88m89m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 73.6mTWD 123.9mTWD 34.6mTWD 137.9mTWD 111.7mTWD 118.3mTWD 74.5mTWD 56.0mTWD 77.6mTWD 45.3m
Capital spending−TWD 3.7m−TWD 44.3m−TWD 35.5m−TWD 70.9m−TWD 117.1m−TWD 139.0m−TWD 393.7m−TWD 275.3m−TWD 28.2m−TWD 32.6m
Free cash flowTWD 69.9mTWD 79.7m−TWD 941,000TWD 67.0m−TWD 5.5m−TWD 20.7m−TWD 319.2m−TWD 219.3mTWD 49.3mTWD 12.8m
Dividends paid−TWD 69.2m−TWD 43.3m−TWD 60.5m−TWD 95.0m−TWD 60.4m−TWD 71.1m−TWD 133.4m−TWD 133.4m−TWD 133.4m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 103.3mTWD 89.2mTWD 100.7mTWD 88.9mTWD 112.2mTWD 99.5mTWD 91.0mTWD 83.8m
Gross profitTWD 61.1mTWD 48.2mTWD 62.7mTWD 55.5mTWD 70.9mTWD 62.6mTWD 46.8mTWD 52.1m
Operating incomeTWD 14.7m−TWD 7.2mTWD 11.8mTWD 7.5mTWD 25.3mTWD 12.7m−TWD 2.5mTWD 3.8m
Net incomeTWD 15.5mTWD 4.1mTWD 24.8mTWD 24.7m−TWD 8.7mTWD 16.5mTWD 2.1mTWD 5.7m
Diluted earnings per share0.180.050.320.32-0.110.210.020.07
Cash from operationsTWD 26.0mTWD 15.0mTWD 49.0m−TWD 4.0m−TWD 2.0mTWD 31.0mTWD 70.0mTWD 9.0m
Capital spending————−TWD 2.0m—−TWD 1.0m−TWD 10.0m
Free cash flow————−TWD 4.0m—TWD 69.0m−TWD 1.0m
Total assetsTWD 1.67bnTWD 1.70bnTWD 1.67bnTWD 1.58bnTWD 1.53bnTWD 1.74bnTWD 1.71bnTWD 1.68bn
Cash and short-term investmentsTWD 354.6mTWD 456.9mTWD 432.8mTWD 382.5mTWD 356.2mTWD 457.0mTWD 425.8mTWD 360.1m
DebtTWD 88.6mTWD 82.3mTWD 77.5mTWD 73.0mTWD 74.0mTWD 80.8mTWD 84.4mTWD 81.3m
Shareholders' equityTWD 1.31bnTWD 1.29bnTWD 1.33bnTWD 1.28bnTWD 1.24bnTWD 1.31bnTWD 1.35bnTWD 1.35bn

Financial ratios

Data as of 2 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin62.7%61.8%66.4%69.7%69.9%66.2%
Operating margin14.4%17.8%9.2%18.2%32.8%23.9%
Net margin14.3%14.9%10.4%15.5%26.4%18.7%
Return on equity4.3%4.2%2.5%4.2%8.2%4.6%
Return on assets3.4%3.4%2.0%3.4%6.7%3.8%
Free cash flow yield5.8%11.2%4.7%14.1%15.4%17.4%
Revenue growth4.1%21.2%-13.7%-13.9%31.6%-6.1%
Earnings growth-0.1%73.5%-42.1%-49.6%85.8%6.0%
Current ratio4.28x3.87x3.18x3.24x4.17x6.28x
Debt to equity0.06x0.06x0.02x0.00x0.00x0.00x
Equity ratio79.9%79.1%79.6%79.7%81.1%82.4%
Interest coverage14.72x18.41x29.94x88.76x182.97x96.41x
R&D as a share of sales11.3%11.7%14.7%16.1%6.0%8.1%
Buybacks as a share of market value10.5%-1.1%0.3%0.1%-0.5%2.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.9%4.3%-2.8%
Operating income-1.4%-5.6%—
Net income0.1%-1.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin62.3%65.0%66.1%63.8%
Operating margin12.4%11.2%17.3%14.2%
Net margin14.5%13.9%17.0%6.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings25.130.964.836.118.731.638.515.144.6-8.9
Price to sales3.64.66.75.64.95.96.45.95.33.9

Dividends and splits

Per share, in the currency the company pays

Paid for 3 years. Last went ex-dividend on 8 Apr 2026.

FY2026FY2025FY2024FY2023FY2021FY2020FY2019FY2013
Paid in the year0.800.800.500.700.570.801.500.496
  • 100-to-79.404 reverse split · 18 Dec 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.